Fujita Kohei, Yamamoto Yuki, Kanai Osamu, Okamura Misato, Nakatani Koichi, Mio Tadashi
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Open Forum Infect Dis. 2020 Mar 7;7(3):ofaa067. doi: 10.1093/ofid/ofaa067. eCollection 2020 Mar.
Immunotherapy with immune checkpoint inhibitors (ICIs), while ameliorating lung cancer, can cause infectious diseases, including tuberculosis, in addition to immune-related noninfectious complications. In the clinical setting, the efficacy of ICIs to treat mycobacterial infection remains controversial. We report 3 cases of acute complex lung disease during immunotherapy with ICIs.
免疫检查点抑制剂（ICI）免疫疗法在改善肺癌的同时，除了会引发免疫相关的非感染性并发症外，还可能导致包括结核病在内的感染性疾病。在临床环境中，ICI治疗分枝杆菌感染的疗效仍存在争议。我们报告了3例在ICI免疫治疗期间发生的急性复杂性肺部疾病病例。
